Telescope Innovations Reports Significant Milestones and Financial Results of Fiscal Year 2025

Executive Summary

• Telescope Innovations reported FY 2025 revenue of CAD 5.8 M, up from CAD 4.4 M in FY 2024.
• Adjusted EBITDA recorded a loss of CAD 402 K, widening from the prior‑year loss of CAD 152 K.
• The company highlighted key operational milestones, including the first deployment of its Self‑Driving Lab for Pfizer in Korea and the shipment of battery‑grade lithium sulfide samples to North American and Asian battery manufacturers.

Key Details

• Revenue: CAD 5.8 M for FY 2025 vs. CAD 4.4 M in FY 2024 (≈32% increase).
• Expenses: CAD 7.3 M for FY 2025 vs. CAD 5.8 M in FY 2024.
• Adjusted EBITDA: Loss of CAD 402 K for FY 2025 vs. loss of CAD 152 K in FY 2024.
• Operational Milestones:
• Continued delivery on multi‑year, funded project with Pfizer for Self‑Driving Lab (SDL) development.
• First SDL deployment for pharmaceutical development in Korea, opening new commercialization opportunities in Asia for FY 26.
• Record sales quarters for DirectInject‑LC™; expansion into Europe and launch in Asia.
• Production of battery‑grade lithium sulfide via proprietary low‑temperature method; first sample shipments to battery industry groups in North America and Asia.
• CEO Quote: Henry Dubina emphasized the transition from development to commercialization, noting growing validation across multiple end markets.

Notable Quotes

“These results reflect the growing validation of Telescope's technology across multiple end markets… FY 2025 marked an important transition from development to commercialization.” – Henry Dubina, CEO

Materiality Assessment: Material – Neutral (the release provides full-year financial performance and significant operational updates that are material to investors.)